Effect of the COVID-19 pandemic on cancer treatment and research

Kamal S. Saini(National Health Service), Begoña de las Heras(Covance (United States)), Javier de Castro(Hospital Universitario La Paz), Ramachandran Venkitaraman(National Health Service), Martine Poelman(Covance (United States)), Gopalakrishnan Srinivasan(National Health Service), Monika Lamba Saini(HistoGeneX (Belgium)), Sanjeev Verma, Manuela Leone(Covance (United States)), Philippe Aftimos(Université Libre de Bruxelles), Giuseppe Curigliano(University of Milan)
The Lancet Haematology
April 24, 2020
10.1016/s2352-3026(20)30123-x
Cited by 161Open Access
Full Text

Abstract

Related Papers

COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta, Daniel F. McAuley, Michael Brown et al.|The Lancet|2020|10.2k
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy
Graziano Onder, Giovanni Rezza, Silvio Brusaferro|JAMA|2020|4.5k
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China
Li Zhang, Fangfang Zhu, Li Xie et al.|Annals of Oncology|2020|1.5k
The official French guidelines to protect patients with cancer against SARS-CoV-2 infection
Benoît You, Alain Ravaud, Anne Canivet et al.|The Lancet Oncology|2020|189
Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients
Emily M. Eichenberger, Rosemary Soave, Dana Zappetti et al.|Bone Marrow Transplantation|2018|45